IRAK4 inhibitor / Merck (MSD) - LARVOL DELTA

IRAK4 Degrader Combines Degradation and Kinase Inhibition to Achieve Functional Effect (FOCIS 2026) - "Abstract Text: Aberrant activation of the immune system through toll-like receptors (TLRs) and pro-inflammatory cytokines drives the pathogenesis of multiple autoimmune and autoinflammatory diseases. Across in vitro, ex vivo and in vivo models, IRAK4 degradation enhanced cytokine inhibition compared to kinase inhibition alone under TLR4-driven and IL-1R-driven stimulation. However, under TLR7/8 stimulation, kinase inhibition was the dominant mechanism of action, indicating that the relative contributions of IRAK4's kinase and scaffolding functions are context-dependent."

Atopic Dermatitis • Dermatitis • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • IL1R1 • IRAK4 • TLR4 • TLR7

Targeting of Various Inflammatory Circuits Does Not Ameliorate Ineffective Hematopoiesis: Results of the Lucas and Canfire Studies Investigating IRAK4 or IL-1β Blockade to Target Anemia in Lower-Risk MDS (ASH 2024) - "Emavusertib treatment was associated with a reduction in neutrophil counts...Canakinumab treatment was well-tolerated with no reported SAEs...Despite the observed anti-inflammatory effects in the bone marrow, in LUCAS there was a paradoxical increase in inflammatory markers in peripheral blood, potentially due to compensatory mechanisms. These findings suggest that targeting multiple inflammatory pathways simultaneously may offer a more promising therapeutic strategy, such as the combination of IL-1β and IRAK4 inhibitors."

Anemia • Cardiovascular • Hematological Disorders • Hematological Malignancies • Infectious Disease • Myelodysplastic Syndrome • Myeloproliferative Neoplasm • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • ASXL1 • CSF1 • IL10 • IL15 • IL1B • IL1R1 • IL7 • IRAK4 • SETBP1 • U2AF1